RxDoctor Payments Data

Latha Nair, MD

Psychiatry · Santa Cruz, CANPI 1164527560

Payments from drug & device makers

$451,167in general payments, 2019–2025

Across 602 payments — averaging $749.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$261K
  • Alkermes, Inc.$88K
  • Neurocrine Biosciences, Inc.$49K
  • Otsuka America Pharmaceutical, Inc.$25K
  • Indivior Inc.$18K
  • Sunovion Pharmaceuticals Inc.$9K
  • plus $1K from 3 others

What the payments were for

  • Consulting fees$22,2815%
  • Speaking & faculty fees$326,99472%
  • Travel & lodging$86,70919%
  • Food & beverage$15,1843%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$451,167 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$18,891
Medicare patients
118
Services billed
197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate69$243,818
Olanzapine OdtOlanzapine105$11,688
Chlorpromazine Hcl16$8,755
Clozapine80$8,098
Quetiapine Fumarate82$5,343
Divalproex Sodium35$4,124
Paliperidone ErPaliperidone12$3,965
Divalproex Sodium ErDivalproex Sodium21$3,414
Olanzapine65$3,379
Thiothixene12$2,024
Valproic AcidValproic Acid (As Sodium Salt)23$1,885
Aripiprazole17$1,697
Hydroxyzine Hcl26$1,419
Benztropine Mesylate47$1,161
Lorazepam61$1,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$260,847$243,81869 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Santa Cruz

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →